KFDA approves Requip PD tablets, once-daily non-ergot dopamine agonist
Published: 2008-06-25 06:58:00
Updated: 2008-06-25 06:58:00
GlaxoSmithKline announced the approval of Requip PD (ropinirole extended-release tablets) in Korea for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The product will be available in pharmacies in the first half of 2009.
Requip PD, an extended-release and once-daily...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
